KUALA LUMPUR, Dec 13 – SuperDNA Sdn Bhd, a privately held Malaysian genetic testing company, and DOC2US, Malaysia’s leading digital health platform and largest e-prescriptions issuer, have signed a memorandum of understanding (MoU) to provide Malaysians with a better preventive health ecosystem through its bundled packages for genetic testing and blood screening.
The collaboration looks to address the growing occurrence of non-communicable diseases (NCD) amongst Malaysians with nearly two-thirds of adult Malaysians suffering from at least one type of NCD. Through holistic health screening solutions, both parties hope to boost personalised preventive health care and thereby address this growing concern.
Commenting on the collaboration, SuperDNA chief executive officer Dr. Stefanie Chow said: “This collaboration with DOC2US is a great milestone for SuperDNA. DOC2US is the first tele-health care provider we are partnering with, and we are thrilled to be working with Malaysia’s leading digital health and e-prescription platform.”
“This collaboration will benefit many Malaysians, improving access to both genetic testing and blood screening at one go. This will allow them to gain deeper insights and have a better understanding of their overall health conditions, thus enabling them to make informed decisions to improve their health. Personalized medicine is the future of healthcare, and genetic testing is the tool that makes it possible,” she added.
This MOU signifies the first step towards a long and collaborative partnership between SuperDNA and DOC2US, who both share core beliefs of preventive health.
Elaborating on the importance of this partnership, DOC2US chief executive officer and co-founder Dr Raymond Choy said: “Malaysian health care is on a nationwide path towards wellness and preventive health care. Through this partnership, both DOC2US and SuperDNA will front preventive health care initiatives and precision medicine to address the nation’s ageing population and an increasing number of non-communicable diseases”.
“The data obtained from precision medicine coupled with clinical data will provide better-personalised insights to both healthcare professionals and patients. As a result, early detection and more accurate diagnosis will improve patient outcomes and diagnosis through the amalgamation of genetic testing and telemedicine.” he added.
The agreement was duly endorsed with the signatures of Dr Chow and Dr Choy, witnessed by Fionne Teoh, general manager of SuperDNA and Eng Kwang Meng, chief strategy officer of DOC2US.
